Marvel Biosciences Corp. , and its wholly owned subsidiary, Marvel Biotechnology Inc. , today reported promising interim results from its acute study on MB-204 conducted by Professor Emmanuel Planel.
Marvel Biosciences Corp. and its wholly owned subsidiary, Marvel Biotechnology Inc. , is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute.